173 related articles for article (PubMed ID: 37555986)
1. Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data.
Gomaa S; Kelly WK; Mitchell E; Storozynsky E; Zeigler-Johnson C; Juon HS; Wen KY
World J Urol; 2023 Sep; 41(9):2351-2357. PubMed ID: 37555986
[TBL] [Abstract][Full Text] [Related]
2. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer.
Derweesh IH; Diblasio CJ; Kincade MC; Malcolm JB; Lamar KD; Patterson AL; Kitabchi AE; Wake RW
BJU Int; 2007 Nov; 100(5):1060-5. PubMed ID: 17868420
[TBL] [Abstract][Full Text] [Related]
3. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
4. Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study.
Wong C; Chu P; Teoh J; Chiu P; Yee CH; Chau L; Chan M; Wan H; Leung S; Ng CF
Int Urol Nephrol; 2022 May; 54(5):993-1000. PubMed ID: 35217907
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
Liu JM; Chen YT; Wu CT; Hsu WL; Hsu RJ
Prostate; 2022 May; 82(7):809-815. PubMed ID: 35226371
[TBL] [Abstract][Full Text] [Related]
6. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
[TBL] [Abstract][Full Text] [Related]
7. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
Eur Urol; 2013 Jul; 64(1):159-66. PubMed ID: 22537796
[TBL] [Abstract][Full Text] [Related]
8. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.
Matsushima H; Taguchi T; Kodama S; Okubo N; Saito K; Jabłońska K; Fukumoto S; Matsumoto T
J Bone Miner Metab; 2024 Mar; 42(2):223-232. PubMed ID: 38493435
[TBL] [Abstract][Full Text] [Related]
11. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
12. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
[TBL] [Abstract][Full Text] [Related]
13. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
[TBL] [Abstract][Full Text] [Related]
14. Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.
Tully KH; Nguyen DD; Herzog P; Jin G; Noldus J; Nguyen PL; Kibel AS; Sun M; McGregor B; Basaria S; Trinh QD
Eur Urol Oncol; 2021 Feb; 4(1):66-72. PubMed ID: 31624049
[TBL] [Abstract][Full Text] [Related]
15. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.
Wang C; Raldow AC; Nickols NG; Nguyen PL; Spratt DE; Dess RT; Yu JB; King CR; Chu FI; Chamie K; Litwin MS; Saigal CS; Reiter RE; Liu ST; Rettig MB; Chang AJ; Steinberg ML; Kupelian PA; Kishan AU
Eur Urol Oncol; 2021 Apr; 4(2):327-330. PubMed ID: 31411981
[TBL] [Abstract][Full Text] [Related]
16. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
17. Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania.
Drevinskaite M; Patasius A; Kincius M; Urbonas V; Smailyte G
BMJ Open; 2021 Jul; 11(7):e045797. PubMed ID: 34321292
[TBL] [Abstract][Full Text] [Related]
18. Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer.
Bradley MC; Zhou Y; Freedman AN; Yood MU; Quesenbery CP; Haque R; Van Den Eeden SK; Cassidy-Bushrow AE; Aaronson D; Potosky AL
Cancer Causes Control; 2018 Aug; 29(8):785-791. PubMed ID: 29959604
[TBL] [Abstract][Full Text] [Related]
19. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
[TBL] [Abstract][Full Text] [Related]
20. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
